Interleukins in Platelet Biology: Unraveling the Complex Regulatory Network
-
Published:2024-01-13
Issue:1
Volume:17
Page:109
-
ISSN:1424-8247
-
Container-title:Pharmaceuticals
-
language:en
-
Short-container-title:Pharmaceuticals
Author:
Huang Miao1, Wang Long2, Zhang Qianhui1, Zhou Ling2, Liao Rui2, Wu Anguo2ORCID, Wang Xinle3, Luo Jiesi3ORCID, Huang Feihong2, Zou Wenjun1, Wu Jianming34ORCID
Affiliation:
1. State Key Laboratory of Southwestern Chinese Medicine Resources, School of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, China 2. Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou 646000, China 3. Department of Physiology, School of Basic Medical Sciences, Southwest Medical University, Luzhou 646000, China 4. The Key Laboratory of Medical Electrophysiology, Institute of Cardiovascular Research, Ministry of Education of China, Luzhou 646000, China
Abstract
Interleukins, a diverse family of cytokines produced by various cells, play crucial roles in immune responses, immunoregulation, and a wide range of physiological and pathological processes. In the context of megakaryopoiesis, thrombopoiesis, and platelet function, interleukins have emerged as key regulators, exerting significant influence on the development, maturation, and activity of megakaryocytes (MKs) and platelets. While the therapeutic potential of interleukins in platelet-related diseases has been recognized for decades, their clinical application has been hindered by limitations in basic research and challenges in drug development. Recent advancements in understanding the molecular mechanisms of interleukins and their interactions with MKs and platelets, coupled with breakthroughs in cytokine engineering, have revitalized the field of interleukin-based therapeutics. These breakthroughs have paved the way for the development of more effective and specific interleukin-based therapies for the treatment of platelet disorders. This review provides a comprehensive overview of the effects of interleukins on megakaryopoiesis, thrombopoiesis, and platelet function. It highlights the potential clinical applications of interleukins in regulating megakaryopoiesis and platelet function and discusses the latest bioengineering technologies that could improve the pharmacokinetic properties of interleukins. By synthesizing the current knowledge in this field, this review aims to provide valuable insights for future research into the clinical application of interleukins in platelet-related diseases.
Funder
National Natural Science Foundation of China State Key Laboratory of Southwestern Chinese Medicine Resources Sichuan Science and Technology Program
Subject
Drug Discovery,Pharmaceutical Science,Molecular Medicine
Reference135 articles.
1. The Normal Megakaryocyte Concentration in Aspirated Human Bone Marrow;Ebaugh;Blood,1951 2. Regulating billions of blood platelets: Glycans and beyond;Grozovsky;Blood,2015 3. Unraveling mechanisms that control platelet production;Italiano;Semin. Thromb. Hemost.,2013 4. Acquired platelet disorders;Casari;Thromb. Res.,2016 5. Palma-Barqueros, V., Revilla, N., Sanchez, A., Zamora Canovas, A., Rodriguez-Alen, A., Marin-Quilez, A., Gonzalez-Porras, J.R., Vicente, V., Lozano, M.L., and Bastida, J.M. (2021). Inherited Platelet Disorders: An Updated Overview. Int. J. Mol. Sci., 22.
|
|